ASCO: Continuing avastin with 2nd-line chemo ups survival
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal ...
Cancer
Jun 05, 2012 |
not rated yet |
0
Drug cocktail boosts ovarian cancer survival time
A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.
Cancer
Jun 02, 2012 |
not rated yet |
0
Adjuvant radiochemotherapy has lasting benefit in gastric cancer
(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival ...
Cancer
May 18, 2012 |
1 / 5 (1) |
0
ASCO: For chemo's nausea, olanzapine beats metoclopramide
(HealthDay) -- For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment ...
Cancer
May 17, 2012 |
not rated yet |
0
New method may help detect marker for Alzheimer's disease earlier
Use of a new drug to detect the beta-amyloid plaques in the brain that are hallmark signs of Alzheimer's disease may help doctors diagnose the disease earlier, according to research that will be presented as part of the Emerging ...
Alzheimer's disease & dementia
Apr 16, 2012 |
not rated yet |
0
Baseline hormone levels may predict survival in metastatic, castration-resistant prostate cancer
Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according ...
Cancer
Apr 03, 2012 |
not rated yet |
0
Harmless human virus may be able to boost the effects of chemotherapy
A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.
Cancer
Apr 03, 2012 |
5 / 5 (1) |
0
Prophylaxis with apixaban feasible for cancer patients
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...
Cancer
Mar 29, 2012 |
not rated yet |
0
Merck blood thinner shows mixed results: study
An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.
Cardiology
Mar 24, 2012 |
not rated yet |
0
Japan's DSP to buy US cancer start-up for $2.6 bn
Japanese drugs giant Dainippon Sumitomo Pharma will buy US biotechnology cancer specialist Boston Biomedical for a price that could hit $2.6 billion, the companies announced Thursday.
Cancer
Mar 01, 2012 |
5 / 5 (1) |
0
Combination therapy may enhance gemcitabine activity
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Di ...
Cancer
Feb 28, 2012 |
3 / 5 (2) |
0
Many lung cancer patients get radiation therapy that may not prolong their lives
A new study has found that many older lung cancer patients get treatments that may not help them live longer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that p ...
Cancer
Feb 13, 2012 |
5 / 5 (1) |
0
New drug extends survival in patients with drug-resistant prostate cancer
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression ...
Cancer
Feb 01, 2012 |
5 / 5 (1) |
0
|
AML patients have high response rate with vorinostat added to treatment
Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center ...
Cancer
Dec 13, 2011 |
not rated yet |
0
Study shows new medication effectively treats underlying cause of cystic fibrosis
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients ...
Medical research
Nov 02, 2011 |
not rated yet |
0
